BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19286849)

  • 1. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
    Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
    J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
    Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
    Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
    Zhong D; Wu C; Bai J; Hu C; Xu D; Wang Q; Zeng X
    Medicine (Baltimore); 2020 Apr; 99(16):e19695. PubMed ID: 32311947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
    Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
    BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia.
    Ichiyasu H; Ichikado K; Yamashita A; Iyonaga K; Sakamoto O; Suga M; Kohrogi H
    Respiration; 2012; 83(3):190-7. PubMed ID: 21555868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
    Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
    Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
    Elhaj M; Charles J; Pedroza C; Liu X; Zhou X; Estrada-Y-Martin RM; Gonzalez EB; Lewis DE; Draeger HT; Kim S; Arnett FC; Mayes MD; Assassi S
    J Rheumatol; 2013 Jul; 40(7):1114-20. PubMed ID: 23588945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
    Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.